Clinical data | |
---|---|
Trade names | Minnebro |
Other names | CS-3150; XL-550 |
Routes of administration | By mouth |
Drug class | Antimineralocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H21F3N2O4S |
Molar mass | 466.48 g·mol−1 |
3D model ( JSmol) | |
| |
|
Esaxerenone ( INN ) (brand name Minnebro; developmental code names CS-3150, XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the treatment of hypertension. [1] [2] [3] It acts as a highly selective silent antagonist of the mineralocorticoid receptor (MR), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the MR relative to the existing antimineralocorticoids spironolactone and eplerenone. [1] [2] [3] As of January 2019, esaxerenone is in phase III clinical trials for diabetic nephropathies. [1]